Lupin share price hits 52-week high on launch of overactive bladder drug in US
Lupin share price rose over 1% to a 52-week high after the FDA approved its generic Mirabegron tablets for overactive bladder, projected to generate $1.6 billion in annual US sales. Lupin and Zydus will have six months of exclusivity amid ongoing litigation.